{"id":"intermediate-dose-enoxaparin-unfractionated-heparin","safety":{"commonSideEffects":[{"rate":"null","effect":"Hemorrhage"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Osteoporosis"}]},"_chembl":{"chemblId":"CHEMBL1201476","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to a decrease in the formation of blood clots and an increase in the breakdown of existing clots. Enoxaparin and unfractionated heparin are both anticoagulants that are used to prevent and treat deep vein thrombosis and pulmonary embolism.","oneSentence":"Enoxaparin and unfractionated heparin work by inhibiting the coagulation cascade, specifically by activating antithrombin and inhibiting thrombin and factor Xa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:27.571Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT06845423","phase":"PHASE4","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-16","conditions":"Venous Thromboembolism (VTE), Post Partum Women","enrollment":2400},{"nctId":"NCT04367831","phase":"PHASE4","title":"Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-05-02","conditions":"COVID-19, Venous Thromboses, Arterial Thrombosis","enrollment":94},{"nctId":"NCT04427098","phase":"PHASE2","title":"Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2020-05-22","conditions":"COVID-19","enrollment":301},{"nctId":"NCT06662253","phase":"PHASE2, PHASE3","title":"Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Alexandre Tran","startDate":"2025-01","conditions":"Venous Thromboembolism (VTE), Trauma Related Injuries","enrollment":150},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT02604238","phase":"PHASE3","title":"Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism","status":"WITHDRAWN","sponsor":"Azienda U.S.L. 1 di Massa e Carrara","startDate":"2016-03","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT04406389","phase":"PHASE4","title":"Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-13","conditions":"COVID-19","enrollment":14},{"nctId":"NCT04646655","phase":"PHASE3","title":"Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2020-07-27","conditions":"Covid19, Thrombosis","enrollment":142},{"nctId":"NCT05901337","phase":"NA","title":"Cupping Therapy on Immune System in Post Covid -19","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-03-07","conditions":"Covid-19 Patients","enrollment":76},{"nctId":"NCT01828697","phase":"PHASE4","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04-24","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1110},{"nctId":"NCT04377997","phase":"PHASE2","title":"Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-15","conditions":"Cardiovascular Diseases, COVID-19","enrollment":300},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT04401293","phase":"PHASE3","title":"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-04-26","conditions":"Sars-CoV2, COVID","enrollment":257},{"nctId":"NCT04486508","phase":"PHASE3","title":"Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19","status":"COMPLETED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2020-07-30","conditions":"Covid19","enrollment":600},{"nctId":"NCT04485429","phase":"PHASE3","title":"Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia","status":"WITHDRAWN","sponsor":"D'Or Institute for Research and Education","startDate":"2020-07-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04394377","phase":"PHASE4","title":"Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial","status":"COMPLETED","sponsor":"Brazilian Clinical Research Institute","startDate":"2020-06-21","conditions":"Coronavirus Infection","enrollment":615},{"nctId":"NCT04520620","phase":"PHASE4","title":"Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2020-05-02","conditions":"Sars-CoV2","enrollment":""},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT01589393","phase":"NA","title":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)","status":"COMPLETED","sponsor":"McMaster University","startDate":"2010-09","conditions":"Traumatic Intracranial Haemorrhage","enrollment":52},{"nctId":"NCT02696330","phase":"PHASE4","title":"Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2015-09","conditions":"Female , Infertility","enrollment":150},{"nctId":"NCT01356992","phase":"PHASE3","title":"Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation","status":"TERMINATED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2012-07","conditions":"Non ST Segment Elevation Myocardial Infarction, Unstable Angina","enrollment":62},{"nctId":"NCT02260908","phase":"NA","title":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage - Pilot Study","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2014-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":300},{"nctId":"NCT01164046","phase":"PHASE3","title":"Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2010-08","conditions":"Venous Thromboembolism, Neoplasms","enrollment":56},{"nctId":"NCT02240927","phase":"NA","title":"Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves","status":"UNKNOWN","sponsor":"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","startDate":"2010-01","conditions":"Pregnancy, Heart; Complications, Valve, Prosthesis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intermediate dose anticoagulation"],"phase":"phase_3","status":"active","brandName":"intermediate dose Enoxaparin/ unfractionated heparin","genericName":"intermediate dose Enoxaparin/ unfractionated heparin","companyName":"Rajaie Cardiovascular Medical and Research Center","companyId":"rajaie-cardiovascular-medical-and-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin and unfractionated heparin work by inhibiting the coagulation cascade, specifically by activating antithrombin and inhibiting thrombin and factor Xa. Used for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}